Australia's most trusted
source of pharma news
Wednesday, 25 February 2026
Posted 25 February 2026 AM
Gilead Sciences has inked a deal to buy Arcellx for US$7.8 billion, setting up a red-hot rivalry with Johnson & Johnson and BMS in the CAR T space.
Like Johnson & Johnson’s Carvykti and BMS’ Abecma, Arcellx’s anito-cel, short for anitocabtagene autoleucel, is a BCMA-directed CAR T-cell therapy for patients with relapsed and refractory multiple myeloma patients – and it’s on the cusp of FDA approval.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.